Global News and Digital Insights
for the Healthcare Industry

Medtech company for lung cancer diagnosis receives $14m

Optellum, an AI-powered platform for early-stage lung cancer detection and treatment, has secured a $14 million in Series A funding round. This will allow Optellum to expand its base, enable commercial launches in the UK and US, and speed up R&D. Mercia led the funding round with other investors like Intuitive Ventures (Sunnyvale, CA, USA) and Black Opal Ventures (New York, NY, USA). Existing investors, including St John’s College in the University of Oxford, IQ Capital, and the family office of Sir Martin and Lady Audrey Wood, also participated in the Series A funding round. Optellum is the only medtech company that has been cleared by the FDA, CE-MDR in the EU, and UKCA in the UK for Virtual Noodle Clinic, its software platform.

Read More from PRNewswire

Facebook
Twitter
LinkedIn